RNXT vs RZLT

RenovoRx, Inc. vs Rezolute, Inc. — Valuation Comparison 2026

RNXT

Pharmaceutical Preparations
RenovoRx, Inc.
Quality
4.9
out of 10
Value Trap
24
SAFE
Price
$0.91
Last close
Models
11/13
Active
VS

RZLT

Pharmaceutical Preparations
Rezolute, Inc.
Quality
4.0
out of 10
Value Trap
30
LOW
Price
$3.30
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType RNXT Fair ValueRNXT Upside RZLT Fair ValueRZLT Upside
Bayesian DCF Intrinsic $0.37 -59.1% $0.91 -72.4%
Earnings Power Value Intrinsic $1.13 +27.8%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.48 -47.3% $1.46 -55.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RNXT vs RZLT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RNXT vs RZLT — Which Stock Is More Undervalued?

RNXT scores higher with a 4.9/10 quality rating vs RZLT's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing RenovoRx, Inc. (RNXT) and Rezolute, Inc. (RZLT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RNXT currently trades at $0.91 with a QOC of 4.9/10, while RZLT trades at $3.30 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).